论文部分内容阅读
目的研究外周血高荧光强度淋巴细胞百分比(HFLC)在HIV/AIDS中的变化及临床意义。方法选择62例初诊HIV/AIDS患者作为研究对象,以32名健康人群作为对照组,用血液分析仪检测HFLC,流式细胞仪检测CD4+T、CD8+T细胞的表达,同时分析治疗前后的变化情况。结果 AIDS患者HFLC(3.04%±0.82%)和CD8+T水平(52.69%±10.65%),均显著高于HIV感染组(0.36%±0.10%、39.56%±9.37%)和对照组(0.12%±0.05%、24.72%±4.13%),差异有统计学意义(P<0.05);CD4+T水平(14.70%±4.87%),显著低于HIV感染组(27.49%±8.57%)和对照组(37.68%±4.71%),差异有统计学意义(P<0.05)。AIDS患者治疗6个月后HFLC、CD4+T和CD8+T水平较治疗前差异有统计学意义(P<0.05)。35例采用HAART治疗,5例无效,30例有效,有效与无效患者HFLC、CD4+T和CD8+T水平治疗前后差值差异具有统计学意义(P<0.05)。HIV感染者HFLC与CD4+T水平负相关、与CD8+T水平正相关(P<0.05)。结论外周血HFLC检测有助于评价HIV/AIDS患者的免疫状况,可作为HIV感染疾病进展及疗效监测的快速、简便的新指标。
Objective To study the changes and clinical significance of high fluorescence intensity lymphocytes (HFLC) in HIV / AIDS. Methods Sixty-two newly diagnosed HIV / AIDS patients were selected as experimental subjects and 32 healthy people as control group. HFLC was detected by hematology analyzer. Flow cytometry was used to detect the expression of CD4 + T and CD8 + T cells. Changes. Results The levels of HFLC (3.04% ± 0.82%) and CD8 + T (52.69% ± 10.65%) in AIDS patients were significantly higher than those in HIV infected patients (0.36% ± 0.10%, 39.56% ± 9.37% (P <0.05). The level of CD4 + T (14.70% ± 4.87%) was significantly lower than that in HIV infection group (27.49% ± 8.57%) and the control group (37.68% ± 4.71%), the difference was statistically significant (P <0.05). The levels of HFLC, CD4 + T and CD8 + T in AIDS patients after 6 months treatment were significantly different from those before treatment (P <0.05). There were significant differences in the difference of HFLC, CD4 + T and CD8 + T between 35 cases treated with HAART and 5 cases ineffective, and 30 cases were effective, effective and ineffective (P <0.05). HFLC was negatively correlated with CD4 + T level and positively correlated with CD8 + T level (P <0.05). Conclusion The detection of peripheral blood HFLC can be used to evaluate the immune status of HIV / AIDS patients. It can be used as a quick and easy new indicator for the progress of HIV infection and the monitoring of therapeutic effect.